Peroxisome proliferator-activated receptor delta and cardiovascular disease

Atherosclerosis. 2013 Nov;231(1):95-106. doi: 10.1016/j.atherosclerosis.2013.08.027. Epub 2013 Sep 5.

Abstract

Recent reports have shown that peroxisome proliferator-activated receptor delta (PPARD) plays an important role in different vascular processes suggesting that PPARD is a significant modulator of cardiovascular disease. This review will focus on PPARD in relation to cardiovascular risk factors based on cell, animal and human data. Mouse studies suggest that Ppard is an important metabolic modulator that may have implications for cardiovascular disease (CVD). Specific human PPARD gene variants show no clear association with CVD but interactions between variants and lifestyle factors might influence disease risk. During recent years, development of specific and potent PPARD agonists has also made it possible to study the effects of PPARD activation in humans. PPARD agonists seem to exert beneficial effects on dyslipidemia and insulin-resistant syndromes but safety issues have been raised due to the role that PPARD plays in cell proliferation. Thus, large long term outcome as well as detailed safety and tolerability studies are needed to evaluate whether PPARD agonists could be used to treat CVD in humans.

Keywords: Agonist; Cardiovascular disease; Mouse models; Peroxisome proliferator-activated receptor delta; Risk factors; Single nucleotide polymorphism.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Atherosclerosis / drug therapy
  • Cardiovascular Diseases / genetics*
  • Dyslipidemias / drug therapy
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Humans
  • Insulin Resistance / physiology
  • Macrophages / drug effects
  • Mice
  • Models, Animal
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects
  • Obesity / complications
  • PPAR delta / agonists
  • PPAR delta / genetics*
  • PPAR delta / pharmacology
  • Risk Factors

Substances

  • PPAR delta